CRISPR Therapeutics’ (CRSP) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $82.00 target price on the stock.

Several other equities research analysts also recently weighed in on CRSP. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Tuesday, August 25th. Sanford C. Bernstein raised their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Finally, Morgan Stanley set a $60.00 price objective on CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.06.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $56.92 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The company has a market cap of $5.50 billion, a P/E ratio of -11.96 and a beta of 1.76. The stock has a 50-day moving average of $53.80 and a two-hundred day moving average of $52.90. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The business had revenue of $10.18 million for the quarter. As a group, analysts anticipate that CRISPR Therapeutics will post -4.47 EPS for the current year.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in CRISPR Therapeutics by 175.1% during the 2nd quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Rothschild Investment LLC grew its stake in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $37,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.